Tolebrutinib achieves main goal in HERCULES phase 3 trial, proving to be the first to reduce disability progression in non-relapsing secondary progressive multiple sclerosis.

Grit Biotechnology gains U.S. FDA approval for GT201 investigational new drug application, a genetically modified TIL, after receiving Chinese IND approval.

On September 2, 2024, Arrowhead Pharmaceuticals (referred to as "Arrowhead") announced the results of the Phase 3 PALISADE study for plozasiran in patients with familial chylomicronemia syndrome (FCS).

FDA Grants Emergency Use Authorization to Novavax's Updated COVID-19 Vaccine for Ages 12 and Up.

Pierre Fabre Laboratories gets green light from EC for BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) combo to treat adults with advanced BRAFV600E-mutant NSCLC.

Alnylam Shares In-Depth Findings from Successful Phase 3 HELIOS-B Study of Vutrisiran in ATTR Amyloidosis Cardiomyopathy Patients at ESC Congress.

Orgenesis Reports Favorable Outcomes from a Practical Study on ORG-101 CAR-T Treatment in CD19+ Acute Lymphoblastic Leukemia Patients.

Johnson & Johnson aims for initial approval of nipocalimab to treat a wide range of patients with antibody-positive generalized myasthenia gravis.

Merck has recently divulged advancements pertaining to two pivotal Phase 3 clinical trials, designated as KEYNOTE-867 and KEYNOTE-630.

Rallybio Unveils RLYB212's Phase 1 Exploratory Study Outcomes in Blood Clotting & Coagulation Dynamics.

Bayer has disclosed the enrollment of the inaugural patient into the international Phase III SOHO-02 study, a randomized, open-label, multicenter clinical endeavor.

Merck KGaA, headquartered in Darmstadt, Germany, Reveals Initiation of Phase III Trial with Oral Cladribine for Treating Generalized Myasthenia Gravis (gMG), Marking First Patient Administration.